PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTocilizumab
Actemra, Roactemra(tocilizumab)
Actemra, RoActemra, Tofidence, Tyenne (tocilizumab) is an antibody pharmaceutical. Tocilizumab was first approved as Roactemra on 2009-01-15. It is used to treat cytokine release syndrome, giant cell arteritis, juvenile arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat arthritis, cytokine release syndrome, giant cell arteritis, and rheumatoid arthritis.
Download report
Favorite
COVID-19
Case Study: COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Actemra, Tofidence, Tyenne
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tocilizumab
Tradename
Proper name
Company
Number
Date
Products
ActemratocilizumabGenentechN-125276 RX2010-01-08
3 products
ActemratocilizumabGenentechN-125472 RX2013-10-21
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
actemraBiologic Licensing Application2018-10-01
actemra actemra actpenBiologic Licensing Application2024-11-06
avtozmaBiologic Licensing Application2025-01-31
tocilizumab-anohBiologic Licensing Application2025-01-31
tofidenceBiologic Licensing Application2025-03-17
tyenneBiologic Licensing Application2024-12-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cytokine release syndrome—D000080424D89.83
juvenile arthritisEFO_1002007D001171M08
rheumatoid arthritisEFO_0000685D001172M06.9
giant cell arteritisEFO_1001209D013700M31.6
Agency Specific
FDA
EMA
Expiration
Code
tocilizumab, Actemra, Genentech, Inc.
2028-03-04Orphan excl.
2024-08-30Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC07: Tocilizumab
HCPCS
Code
Description
J3262
Injection, tocilizumab, 1 mg
M0249
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
M0250
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
Q0249
Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Clinical
Clinical Trials
834 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTocilizumab
INNtocilizumab
Description
Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was developed by Hoffmann–La Roche and Chugai.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1237022
ChEBI ID—
PubChem CID—
DrugBankDB06273
UNII IDI031V2H011 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Actemra – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 76,171 documents
View more details
Safety
Black-box Warning
Black-box warning for: Actemra, Actemra actemra actpen, Avtozma, Tocilizumab-anoh, Tofidence, Tyenne
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
112,495 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use